1. Home
  2. KITT vs PHGE Comparison

KITT vs PHGE Comparison

Compare KITT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nauticus Robotics Inc.

KITT

Nauticus Robotics Inc.

HOLD

Current Price

$1.21

Market Cap

8.1M

Sector

Industrials

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.59

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KITT
PHGE
Founded
2014
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
6.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KITT
PHGE
Price
$1.21
$4.59
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
12.2M
62.5K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,688,840.00
N/A
Revenue This Year
$2,936.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
95.38
N/A
52 Week Low
$0.71
$4.10
52 Week High
$54.36
$22.06

Technical Indicators

Market Signals
Indicator
KITT
PHGE
Relative Strength Index (RSI) 45.95 74.68
Support Level $0.71 $4.10
Resistance Level $1.70 $4.91
Average True Range (ATR) 0.19 0.30
MACD 0.08 0.39
Stochastic Oscillator 49.49 77.56

Price Performance

Historical Comparison
KITT
PHGE

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: